Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$269.00
pos +0.47
+0.18%
Today's Range: 267.74 - 270.07 | BIIB Avg Daily Volume: 1,741,200
Last Update: 03/30/17 - 3:59 PM EDT
Volume: 1,448,706
YTD Performance: 2.75%
Open: $269.13
Previous Close: $268.53
52 Week Range: $223.02 - $338.51
Oustanding Shares: 215,951,945
Market Cap: 59,194,587,644
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 10 11
Moderate Buy 0 1 1 1
Hold 6 4 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.53 1.66 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.19
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.19 16.20 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.52% 14.41% -0.93%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $5.00 $5.16 $20.94 $22.46
Number of Analysts 19 19 18 20
High Estimate $5.28 $5.38 $21.48 $23.82
Low Estimate $4.65 $4.98 $20.54 $19.18
Prior Year $4.79 $5.21 $20.22 $20.94
Growth Rate (Year over Year) 4.46% -0.88% 3.55% 7.27%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Many want to undo what's been done, but not enough to send the market down.
Bearish
Mar 16, 2017 | 7:13 AM EDT
BIIB was downgraded from Outperform to Market Perform, Leerink Partners said. $300 price target. Spinraza checks suggest a slow start.
There are nearly too many surging sectors to count.
Bullish
Feb 07, 2017 | 7:01 AM EST
BIIB was upgraded to Buy, Citigroup said. $305 price target. See positive risk/reward for the MS product line.
The Fed is simply not a market catalyst this time.
A merger would be smart, profitable ... and attention-grabbing.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Columnist Conversations

The DJIA has been making lows at a fairly regular interval of 101 days. The cycle tools overlaid on the daily ...
this stock continues to move well, momentum is strong. BOUGHT JACK MAY 100 CALL AT 5.25
I have a special guest joining me today, legendary technician Marc Chaikin comes aboard tonight, talking about...
View Chart »  View in New Window » To fail or not to fail is the question.  The video I d...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.